ABVC Stock Overview A clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
ABVC BioPharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ABVC BioPharma Historical stock prices Current Share Price US$0.55 52 Week High US$1.73 52 Week Low US$0.41 Beta 0.70 1 Month Change 6.58% 3 Month Change 17.37% 1 Year Change -61.26% 3 Year Change -98.32% 5 Year Change -98.24% Change since IPO -97.58%
Recent News & Updates
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 Dec 20
ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2) Jul 13 ABVC BioPharma, Inc. announced delayed 10-Q filing May 17
ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024 Mar 15
ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024 Mar 01 ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC Jan 18
See more updates
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 Dec 20
ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2) Jul 13 ABVC BioPharma, Inc. announced delayed 10-Q filing May 17
ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024 Mar 15
ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024 Mar 01 ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC Jan 18
ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024 Dec 30
ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study Dec 07
ABVC BioPharma, Inc. announced delayed 10-Q filing Nov 15
Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study Oct 18
ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement Aug 10 ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million. Aug 01
ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding Jul 28
Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1) Jul 16
ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer Jun 27
ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement May 29
ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia May 24
First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022) May 18
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt Mar 13
ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2) Feb 18
Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference Jan 20
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer Jan 06
ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol Nov 18
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Less than half of directors are independent Nov 16
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder Nov 08
ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601 Nov 03
ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia Oct 06
Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute Oct 05
Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval Sep 24
ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug Sep 23 ABVC BioPharma Receives Non-Compliance Letter from Nasdaq
ABVC BioPharma, Inc. Provides Vitargus Update Aug 19
ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry? Aug 18
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 17
ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M Aug 17
ABVC BioPharma, Inc. Provides Vitargus Update Aug 03
ABVC BioPharma, Inc. Announces Board Changes Jul 15 ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial Jul 13
ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand Jul 01
Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute Jun 30
ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC Jun 17
Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board Jun 10 ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
ABVC BioPharma, Inc. Announces Board Elections May 28
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 18
ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million. May 13
ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject May 12
ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process May 06
Insufficient new directors Apr 27
ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting Apr 27
Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt? Apr 04
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 02
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study Feb 03
ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites Jan 06
Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment? Dec 09
High number of new directors Dec 05
Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020) Nov 18
High number of new directors Sep 19
High number of new directors Sep 18
High number of new directors Sep 16
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study Sep 14
High number of new directors Sep 12
High number of new directors Aug 31
High number of new directors Aug 22
High number of new directors Aug 19
High number of new directors Aug 15
Second quarter 2021 earnings released: US$0.081 loss per share (vs US$0.095 loss in 2Q 2020) Aug 13
High number of new directors Aug 13
ABVC BioPharma, Inc. has completed a Composite Units Offering in the amount of $6.875 million. Aug 06
Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment? Aug 05
High number of new directors Aug 05
American BriVision (Holding) Corporation, Annual General Meeting, Feb 08, 2021 Jan 09
American BriVision (Holding) Corporation announced delayed 10-Q filing Nov 18
American BriVision (Holding) Corporation Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) Nov 10 Shareholder Returns ABVC US Biotechs US Market 7D -15.5% -2.4% -2.1% 1Y -61.3% -8.7% 21.3%
See full shareholder returns
Return vs Industry: ABVC underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: ABVC underperformed the US Market which returned 23.2% over the past year.
Price Volatility Is ABVC's price volatile compared to industry and market? ABVC volatility ABVC Average Weekly Movement 13.8% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: ABVC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ABVC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.
Show more ABVC BioPharma, Inc. Fundamentals Summary How do ABVC BioPharma's earnings and revenue compare to its market cap? ABVC fundamental statistics Market cap US$6.54m Earnings (TTM ) -US$8.24m Revenue (TTM ) US$509.79k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ABVC income statement (TTM ) Revenue US$509.79k Cost of Revenue US$139.97k Gross Profit US$369.82k Other Expenses US$8.61m Earnings -US$8.24m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.67 Gross Margin 72.54% Net Profit Margin -1,616.97% Debt/Equity Ratio 28.0%
How did ABVC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 17:37 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ABVC BioPharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason McCarthy Maxim Group Marla Marin Zacks Small-Cap Research
Show 0 more analysts 
